gepirone monohydrochloride
Trade name: Exxua
Small moleculeapproved
Approved
Sep 22, 2023
Clinical trial activity
1 trials · 2 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 1990 (NCT00000189)
Timeline
Indications
Approved for
Studied for
Mechanism of action
Serotonin 1a (5-HT1a) receptor agonist
May have differential action at presynaptic (agonist) and post-synaptic (partial agonist) 5-HT1A receptors (PMID: 11892924)
- Serotonin 1a (5-HT1a) receptorPARTIAL AGONIST
HTR1A partial agonist
Approval history
- approvedSep 22, 2023
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)CC(=O)N(CCCCN2CCN(c3ncccn3)CC2)C(=O)C1- Mol. weight
- 359.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Black box warning
Sources
- ChEMBLCHEMBL284092 ↗
- ChEMBLCHEMBL1204187 ↗
Also known as
- 4,4-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-2,6-piperidinedione
- ariza
- ariza
- bmy 13805
- bmy-13805
- bmy-13805
- bmy-13805
- gepirone
- gepirone
- gepirone
- gepirone
- gepirone
- gepirone
- gepirone er
- gepirone er
- gepirone er
- gepirone hcl
- gepirone hydrochloride
- gepirone monohydrochloride
- gepirone monohydrochloride
- mj 13805
- mj-13805
- mj 13805-1
- org-13011
- org-13011
- variza
- variza
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00000189 | Phase 2 | Jan 1, 1990 | National Institute on Drug Abuse (NIDA), University of Pennsylvania |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 1990 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 1990 |
2 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Kramer | For profit | NDA | Sep 22, 2023 |